Quick answer: peptide therapy means treating a condition with peptides, short chains of amino acids that act as signals in the body. More than 80 peptide drugs have reached the market since insulin, for conditions including diabetes, cancer, osteoporosis and HIV infection.[1] But the “peptide therapy” offered by many wellness and anti-aging clinics means something different: unapproved compounds such as BPC-157, TB-500 and MOTS-c, for which FDA found little or no human safety data.[6]
This guide explains the two meanings, what the evidence shows for each, the risks, and the legal picture in 2026. If you are new to the topic, start with our beginner’s guide to peptides or the peptide basics hub.
What is peptide therapy?
A peptide is a short chain of amino acids, the same building blocks that make up proteins. Many of the body’s hormones are peptides.
For regulatory purposes, FDA draws the line at 40 amino acids. Since March 23, 2020, any chain longer than 40 amino acids counts as a protein and is regulated as a biological product.[2] That is why insulin, at 51 amino acids, is now treated as a protein rather than a peptide under US law, even though it is often called the first peptide drug.[2]
Two very different things called peptide therapy
| Approved peptide medicines | Unapproved “wellness” peptides | |
|---|---|---|
| Examples | Semaglutide, tirzepatide, liraglutide, tesamorelin | BPC-157, TB-500, MOTS-c, CJC-1295, injectable GHK-Cu |
| Human trials | Required for approval | Few or none |
| FDA review of quality | Yes | No |
| Dosing | On the FDA label | Not established |
| How you get it | Prescription, licensed pharmacy | Clinics, compounding gray zone, “research” sellers |
The rest of this guide treats them separately, because the evidence behind them is not comparable.
Approved peptide therapies
Approved peptide drugs went through clinical trials, and FDA reviewed their safety, effectiveness and manufacturing before they reached pharmacies. Examples:
- GLP-1 medicines: semaglutide is sold as Wegovy for weight reduction, to reduce the risk of heart attack and stroke in adults with heart disease and obesity or overweight, and for a type of fatty liver disease (MASH) with moderate to advanced scarring.[3] Tirzepatide and liraglutide are other examples.
- Tesamorelin: tesamorelin is approved for HIV-associated lipodystrophy, a condition with excess abdominal fat.[4]
- Others: peptide drugs are also used for osteoporosis, multiple sclerosis and chronic pain.[1]
These drugs have known side effects. For Wegovy, the label lists nausea in 44% of people versus 16% on placebo in weight-loss trials, along with diarrhea, vomiting and constipation.[3]
Unapproved peptides: what the evidence shows
Clinic peptides are marketed for injury recovery, anti-aging, energy and fat loss. Independent reviews keep reaching the same conclusion: promising animal data, very little human evidence.
- BPC-157: benefits for tendon and muscle repair are largely unvalidated in human trials. The one human case series on knee pain had no control group and significant flaws.[4] FDA found only small human studies, including 17 people given knee injections.[6] See our BPC-157 profile.
- TB-500: FDA found no studies in which TB-500 was given to people and no animal toxicity studies.[6]
- MOTS-c: FDA identified no human studies or human exposure data.[6]
- CJC-1295: FDA has identified serious adverse events possibly linked to it, including increased heart rate and a whole-body vasodilation (flushing) reaction.[7]
- GHK-Cu injections: no clinical data support injected GHK-Cu for joint or tendon problems.[4]
A 2026 scoping review of six popular peptides found that 67% of the published studies were in animals. The few human studies mostly lacked strong controls, and showed modest improvements at best.[5] A 2026 sports medicine review also noted that the placebo effect, amplified by social media, may explain some of the benefit people report.[11]
Risks of peptide therapy
For approved drugs, the label lists the risks. For unapproved peptides, the risks are largely unknown, and FDA has flagged several concerns:
- Immune reactions. Injected peptides may trigger immune responses, especially when products contain impurities or clumped (aggregated) peptide.[7]
- Unknown product quality. FDA found the TB-500 and MOTS-c substances it reviewed were not well characterized, with missing data on impurities and bacterial contamination.[6]
- Reported reactions. FDA’s adverse event database held a few BPC-157 reports, including injection-site redness and swelling, shortness of breath leading to an emergency visit, and skin and gum darkening in a person also using TB-500. It was unclear whether BPC-157 caused them.[6]
- Theoretical long-term harms. A 2026 review lists contamination, inaccurate dosing, abnormal blood vessel growth and cancer promotion among the potential risks of unregulated injectable peptides.[8]
Read more in our guides to peptide side effects and whether peptides are safe.
Is peptide therapy legal?
- Approved peptides are legal with a prescription from a licensed pharmacy.
- “Research use only” products are not legal for human use. FDA has warned companies that sold semaglutide, tirzepatide and retatrutide labeled “for research purposes” with dosing instructions, and says such products are of unknown quality.[9]
- Compounding: in 2023 FDA placed many popular peptides on a list of substances that may pose significant safety risks in compounding. Many of those nominations, including BPC-157, TB-500 and MOTS-c, were later withdrawn, which moved them off that list without approving them.[7]
- July 2026 votes: FDA staff recommended against adding BPC-157, KPV, TB-500 and MOTS-c to the list of substances pharmacies may compound.[6] FDA’s advisory committee nonetheless voted 8 to 6 in favor of BPC-157, KPV and TB-500, and 7 to 5 for MOTS-c. The votes are not binding, and as of a July 31, 2026 report, none had been added to the list.[10]
Our regulation guide to peptide legality has more detail.
Who should be especially careful
- Anyone with a history of cancer, given the theoretical concerns about growth signaling.[8]
- People who are pregnant or breastfeeding, since unapproved peptides have no safety data in pregnancy.
- Competitive athletes: TB-500 is on the World Anti-Doping Agency’s prohibited list.[6]
- People taking other prescription medicines, because interactions have not been studied.
Questions to ask a clinician or clinic
- Is this peptide FDA-approved for my condition? If not, what human evidence supports it?
- Where is it made, and can you show me the pharmacy and its license?
- What side effects should I watch for, and who do I call if they happen?
- Is there an approved treatment I should try first?
Our guides on how to talk to your doctor about peptides, peptide clinics vs DIY and what results to expect and when can help you prepare. For costs, see does insurance cover peptide therapy.
